Lords Mark Industries and ARKALL Holdings Partner for Caribbean Healthcare Expansion

Lords Mark Industries and ARKALL Holdings Partner for Caribbean Healthcare Expansion​

Lords Mark Industries Limited has entered into a strategic collaboration with Caribbean-based partner ARKALL Holdings Limited to expand its healthcare footprint across the Caribbean region. The partnership aims to establish and operate pathology laboratories and facilitate the commercialization of Lords Mark’s medical devices, equipment, diagnostics, and healthcare portfolio throughout the Caribbean.

The collaboration represents Lords Mark’s official entry into the Caribbean healthcare market. The expansion will follow a phased model, beginning in Trinidad & Tobago and gradually extending to other Caribbean markets over the next three years.

Key Aspects of the Strategic Alliance

ARKALL Holdings Limited will undertake the necessary investments for the proposed Caribbean expansion. This includes funding and establishing and scaling pathology laboratory operations and supporting commercialization activities.

Lords Mark Industries Limited will supply its comprehensive range of products, including IVD products, rapid test kits, biochemistry reagents, pathology laboratory products, medical equipment, and dialysis machines, along with other healthcare solutions.

The company will also provide technical guidance, product knowledge, training, and operational support as needed. ARKALL Holdings Limited will lead the commercialization and market development activities across the agreed Caribbean markets.

The parties will first conduct a market assessment and business planning phase focused on Trinidad & Tobago before rolling out the expansion across the wider Caribbean region.

Market Scope and Financial Projections

The proposed collaboration is designed to create a scalable healthcare platform that integrates pathology and diagnostics infrastructure with access to advanced medical technology and equipment.

Based on internal projections and business planning, Lords Mark Industries Limited expects the phased Caribbean rollout to potentially generate approximately US$100 million in export revenue between fiscal years 2026-27 and 2030-31. Furthermore, the indicative pathology and diagnostics opportunity across the identified Caribbean markets is estimated at approximately US$1.24 billion.

The company clarified that these revenue projections and market opportunity estimates are based on internal management assessments, and actual results may vary depending on market conditions, regulatory approvals, and the pace of expansion.

The details of the partnership and financial scope are summarized below:


Management Commentary

Dr. Sachidanand Upadhyay, Managing Director and CEO of Lords Mark Industries Limited, commented on the partnership, stating that it marks a significant step in taking Lord's Mark's MedTech and healthcare capabilities to a wider international market. He noted that the Caribbean expansion allows the company to combine its medical technology, pathology, and dialysis capabilities with ARKALL's regional commercial presence, positioning the partnership as a long-term platform for expanding its export footprint.

A Senior Management Representative from ARKALL Holdings Limited shared that the Caribbean offers a prime opportunity to strengthen healthcare infrastructure by providing greater access to quality diagnostics and specialized healthcare solutions. The organization aims to build a scalable network, starting with Trinidad & Tobago, to progressively meet the healthcare needs of the Caribbean markets.

Stock Price Movement​

As of 09:31, Lords Mark Industries Ltd shares are edging higher at ₹84.58, representing a +0.59% gain. The stock has ranged throughout the morning, trading between an intraday low of ₹83.00 and a high of ₹85.20.